Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BASH-001
- Development stage
- Preclinical
- Lead developer
- Bash Biotech
- Modality
- Small Molecules
01
Overview
BASH-001 is an investigational small molecule being developed by Bash Biotech (also known as Bash Today) for the treatment of chronic kidney disease (CKD). The program is based on research from the laboratory of Dr. Benjamin Humphreys at Washington University in St. Louis, which utilizes single-cell genomic insights to identify molecular drivers of kidney fibrosis and myofibroblast activation. BASH-001 is designed to target a novel, undisclosed biological pathway to halt or reverse the progression of renal decline. Currently in the preclinical stage of development, it represents the lead candidate in Bash Biotech's pipeline of therapies aimed at restoring kidney function.
Beyond the preview
Go deeper on BASH-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BASH-001.